A recent study validated R3-AFP’s prognostic value in LT recipients with mammalian target of rapamycin inhibitor (mTORi)-based immunosuppression, which could potentially decrease HCC recurrence and improve survival [44]. This evidence concerns the gene MTOR and hepatocellular carcinoma.